Virax Biolabs Group Limited (NASDAQ:VRAX – Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 55,500 shares, a decline of 44.8% from the January 31st total of 100,500 shares. Approximately 4.2% of the shares of the stock are sold short. […]